title: Moderate intake of n-3 fatty acids is associated with stable erythrocyte resistance to oxidative stress in hypertriglyceridemic subjects.
abstract: BACKGROUND
  The important triacylglycerol-lowering capacity of n-3 fatty acids is counterbalanced by their inherent sensitivity to oxidation. Inconsistent results about the latter have been reported in hypertriglyceridemic individuals. After incorporation into cell membranes, n-3 fatty acids may alter membrane-related functions. In view of the distinct composition of hypertriglyceridemic membranes and the prooxidant status in this condition, it can be surmised that cell enrichment with the oxidizable n-3 fatty acids will be associated with an increased hemolytic process.
  
  
  OBJECTIVE
  We sought to evaluate the effect of fish oil consumption on n-3 fatty acid incorporation into erythrocyte membranes and subsequent ex vivo oxidative-stress-induced hemolysis in normotriglyceridemic and hypertriglyceridemic subjects.
  
  
  METHODS
  Sixteen normotriglyceridemic and 12 hypertriglyceridemic subjects were given 6 g fish oil/d for 8 wk. Blood samples were collected before and 4 and 8 wk after treatment. Resistance to 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced hemolysis was assayed in fresh erythrocyte suspensions, and erythrocyte samples were stored at -70 degrees C for later analysis of cholesterol, hemoglobin, fatty acids, vitamin E, and glutathione peroxidase activity.
  
  
  RESULTS
  Fish oil supplementation induced n-3 fatty acid incorporation in normotriglyceridemic and hypertriglyceridemic erythrocyte membranes without decreasing their resistance to AAPH. n-3 Fatty acids significantly protected normotriglyceridemic but not hypertriglyceridemic erythrocytes against hemolysis. In normotriglyceridemic subjects only, the higher resistance to hemolysis correlated with changes in cell vitamin E.
  
  
  CONCLUSIONS
  Although they exhibit a high susceptibility to oxidation, n-3 fatty acids may preserve membrane integrity and represent an added benefit in the treatment of hypertriglyceridemic patients.
authors.affiliation: Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Mabile
authors.forename: A
authors.initials: A
authors.lastname: Piolot
authors.forename: L
authors.initials: L
authors.lastname: Boulet
authors.forename: L J
authors.initials: LJ
authors.lastname: Fortin
authors.forename: N
authors.initials: N
authors.lastname: Doyle
authors.forename: C
authors.initials: C
authors.lastname: Rodriguez
authors.forename: J
authors.initials: J
authors.lastname: Davignon
authors.forename: D
authors.initials: D
authors.lastname: Blache
authors.forename: S
authors.initials: S
authors.lastname: Lussier-Cacan
mesh_terms: D000328:Adult; D000578:Amidines / Q000037:antagonists & inhibitors; D002851:Chromatography, High Pressure Liquid; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism*; D004912:Erythrocytes / Q000187:drug effects*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects
chemical_list: D000578:Amidines; D015525:Fatty Acids, Omega-3; C046728:2,2'-azobis(2-amidinopropane)